诺和诺德命运迎来反转？FDA批准Wegovy新用途——“肝病”

Core Insights - Novo Nordisk's drug Wegovy has received FDA approval for a new indication, leading to a significant stock price increase [1][3] - The approval allows Wegovy to expand its use from weight loss to treating liver disease, providing a competitive edge in the lucrative GLP-1 drug market [3][4] - This development is crucial for Novo Nordisk, especially after a significant market value decline due to intense competition in the obesity market [3][5] Group 1 - Wegovy's stock price surged by up to 5% following the FDA approval, currently stabilizing at a 4.08% increase [1] - The approval signifies a first-mover advantage for Novo Nordisk in the treatment of MASH (metabolic dysfunction-associated steatotic liver disease) [4][6] - Wegovy's new indication is expected to help reverse the company's recent performance struggles in the market [4][5] Group 2 - Wegovy is now approved for treating adults with moderate to severe liver fibrosis associated with MASH, a serious liver condition [6] - The expansion of Wegovy's application is a critical step in supporting the demand for Novo Nordisk's flagship product amid competition from cheaper generics and more effective drugs like Eli Lilly's Zepbound [5][6]